Name: Name:Evatanepag
Brand: AABLOCKS
SKU: AA00BF4O
Rating: 90 (10 reviews)

Technical Information

Catalog Number: AA00BF4O

Chemical Name: Evatanepag

CAS Number: 223488-57-1

Molecular Formula: C25H28N2O5S

Molecular Weight: 468.5652

MDL Number: MFCD09833940

SMILES: OC(=O)COc1cccc(c1)CN(S(=O)(=O)c1cccnc1)Cc1ccc(cc1)C(C)(C)C

Properties

Complexity: 722

Covalently-Bonded Unit Count: 1

Heavy Atom Count: 33

Hydrogen Bond Acceptor Count: 7

Hydrogen Bond Donor Count: 1

Rotatable Bond Count: 10

XLogP3: 4.2

Downstream Synthesis Route

223488-57-1

223490-49-1

[1]Patent:US2005/65133,2005,A1.Locationinpatent:Page/Pagecolumn45

[2]Patent:US6498172,2002,B1

223492-52-2

223488-57-1

[1]Patent:US2005/65133,2005,A1.Locationinpatent:Page/Pagecolumn45

223488-57-1

(3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-aceticacidsodiumsalthemihydrate

[1]Patent:WO2009/27811,2009,A2.Locationinpatent:Page/Pagecolumn15;29-30

[2]Patent:WO2009/27811,2009,A2.Locationinpatent:Page/Pagecolumn15

223488-57-1

1126076-53-6

[1]Patent:WO2009/27811,2009,A2.Locationinpatent:Page/Pagecolumn30-31

Literature fold

Title: Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation.

Journal: Bioorganic & medicinal chemistry letters20090401

Title: CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.

Journal: Drug metabolism and disposition: the biological fate of chemicals20081001

Title: In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist.

Journal: Life sciences20080116

Title: Effects of gestational age on prostaglandin EP receptor expression and functional involvement during in vitro contraction of the guinea pig uterus.

Journal: Prostaglandins, leukotrienes, and essential fatty acids20080101

Title: Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.

Journal: Drug metabolism and disposition: the biological fate of chemicals20050801

Title: Prostaglandin E2 receptor subtype EP-2 is not involved in the induction of non-pregnant guinea pig uterine contractions associated with terminal pregnancy.

Journal: Prostaglandins, leukotrienes, and essential fatty acids20041201

Title: A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research20031101

Title: An EP2 receptor-selective prostaglandin E2 agonist induces bone healing.

Journal: Proceedings of the National Academy of Sciences of the United States of America20030527

Title: Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8.

Title: Judith Plaza, et al. In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity. Allergy Asthma Immunol Res. 2020 Jul;12(4):712-728.

Title: V M Paralkar, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6736-40.

223488-57-1 | Evatanepag